08Feb 2024
Innovent Biologics Announces Acceptance of Mazdutide NDA by NMPA for Chronic Weight Management in China

Innovent Biologics Announces Acceptance of Mazdutide NDA by NMPA for Chronic Weight Management in China

Innovent Biologics announces that the NDA for mazdutide, a GLP-1R/GCGR dual agonist for chronic weight management in adults with obesity or overweight, has been accepted by China's NMPA. Mazdutide, the first of its kind, completed Phase 3 trials successfully. Results showed superiority over placebo in weight reduction and cardiometabolic endpoints. The safety profile remained consistent with previous studies. Detailed results from the GLORY-1 trial will be disclosed in medical conferences or journals later in 2024.

  • #family health

Like

Save

Share